News

Investing.com -- Dyne Therapeutics, Inc. (NASDAQ: DYN) reported a second quarter loss that slightly missed analyst expectations as the clinical-stage biotech company continues to advance its ...
The UK’s new industrial strategy signals a decisive shift toward state-backed innovation, investment, and regulatory reform.
On July 24, 2025, the Federal Trade Commission (“FTC”) and the U.S. Department of Justice (“DOJ”) convened the second of ...